BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

International Journal of Biological and Medical Research (IJBMR)

Original Article
Year : 2026  |  Volume : 17  |  Issue : 3  |  Page : 8608-8611 Full Version
Association of serum magnesium levels with diabetes mellitus and its complications: a cross-sectional study
Int J Biol Med Res. 2026; 17(3): 8608-8611  |  DOI: 10.65048/ijbmr.2026.17.3.8608.1052
Dr. Nitin V. Suryawanshi1*, Dr. MD Ataul Ansari2
1* Associate Professor & HOD, Dept. of General Medicine, Govt. Medical College, Alibag-Raigad- 402201, Maharashtra, India
2 Junior Resident, Dept. of General Medicine, Grant Govt. Medical College, Mumbai- 400008, Maharashtra, India
Correspondence Address :
Dr. Nitin V. Suryawanshi,
Associate Professor & HOD, Dept. of General Medicine,
Govt. Medical College, Alibag-Raigad- 402201, Maharashtra, India E-mail: docnitins@gmail.com
Received: April 5, 2026 Accepted: June 12, 2026 Published: July 3, 2026

Abstract
Background and Aims: Hypomagnesemia is a frequently underrecognized metabolic derangement in diabetes mellitus. This study aimed to determine the association of serum magnesium levels with diabetes mellitus and its microvascular and macrovascular complications. Methods: A hospital-based cross-sectional study was conducted in the Department of Medicine over 18 months. A total of 128 diabetic patients (age ?18 years) were enrolled from a diabetic outpatient clinic. Serum magnesium levels, glycaemic markers (FBS, PPBS, HbA1c), renal function tests, and clinical data were collected. Patients were assessed for microvascular complications (nephropathy, neuropathy, retinopathy) and macrovascular complications (IHD, CVA, PVD). Statistical analysis was performed using SPSS software. Results: Of 128 participants (mean age 53.6 years; 54.7% male), hypomagnesemia (<1.7 mg/dL) was present in 82 patients (64.1%), compared to an expected prevalence of ~5% in the general population (p < 0.003). Diabetic nephropathy was the most common microvascular complication (35.9%), followed by neuropathy (30.5%) and retinopathy (27.3%). Ischemic heart disease was the predominant macrovascular complication (36.7%). Patients with nephropathy and chronic kidney disease had significantly lower mean serum magnesium levels (p < 0.05). An inverse trend was also noted between serum magnesium and HbA1c. Patients on diuretics or proton pump inhibitors (PPIs) demonstrated lower magnesium levels compared to those not on these agents. Conclusions: Hypomagnesemia is highly prevalent among diabetic patients and is significantly associated with nephropathy and chronic kidney disease. Routine monitoring of serum magnesium in diabetic care, especially in patients with renal complications or on diuretics/PPIs, is recommended.
Keywords
Diabetes mellitus, Diabetic complications, Hypomagnesemia, Nephropathy, Serum magnesium

Introduction

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia due to defects in insulin secretion, insulin action, or both. It is a leading cause of morbidity and mortality worldwide, contributing significantly to healthcare burdens through its associated complications, including cardiovascular disease, neuropathy, nephropathy, and retinopathy [1].

Magnesium, the fourth most abundant mineral in the human body and the second most abundant intracellular cation, plays a critical role in over 300 enzymatic reactions, including those governing glucose metabolism, insulin secretion, and cellular energy production [2,3]. It acts as a cofactor for enzymes involved in glycolysis and the citric acid cycle, facilitating insulin-mediated glucose uptake in cells. Low intracellular magnesium has been shown to impair tyrosine kinase activity at the insulin receptor, reduce expression of glucose transporter 4 (GLUT4), and disrupt downstream insulin signaling pathways, all of which contribute to insulin resistance [4,5].

Hypomagnesemia is considerably more common among patients with diabetes mellitus than in the general population, with reported prevalence rates ranging from 13.5% to 47.7% in various studies [6]. The condition is frequently underdiagnosed and may create a vicious cycle: diabetes-induced osmotic diuresis promotes renal magnesium wasting, while hypomagnesemia in turn worsens insulin resistance and glycemic control [7,8]. Magnesium deficiency has further been implicated in the development of diabetic complications through its effects on oxidative stress, endothelial dysfunction, and systemic inflammation [9].

Despite the growing body of evidence linking low serum magnesium to poor glycemic control and diabetic complications, routine measurement of serum magnesium is not universally practiced in diabetic care. This study was therefore conducted to determine the prevalence of hypomagnesemia in a diabetic outpatient population, and to explore its association with key diabetic complications — nephropathy, neuropathy, retinopathy, and cardiovascular disease — as well as with glycemic control and concurrent medication use.

Materials and Method

Study Design and Setting: This was a hospital-based, cross-sectional observational study conducted in the Department of General Medicine over a period of 18 months. The study was approved by the Institutional Ethics Committee and written informed consent was obtained from all participants prior to enrollment.

Study Population and Sample Size: Patients diagnosed with diabetes mellitus (type 1 or type 2) above the age of 18 years attending the diabetic outpatient department (OPD) were eligible for inclusion. Based on a reference study by Kumar P et al., which reported a hypomagnesemia prevalence of 44% in diabetic patients [10], the required sample size was calculated using the formula 4PQ/L² (where P = 44, Q = 56, L = 20% of prevalence), yielding a minimum of 128 participants.

Inclusion Criteria: (1) Patients with diabetes mellitus aged 18 years and above of either gender; (2) individuals providing informed consent and agreeing to blood sampling; (3) stable medical condition for at least three months prior to enrollment, with no recent acute illness or major surgical procedure.

Exclusion Criteria: (1) Pregnant or breastfeeding women; (2) patients with chronic kidney disease (CKD) stages 4 or 5; (3) individuals currently on magnesium supplementation; (4) individuals with other endocrine disorders such as hyperthyroidism or hypoparathyroidism that could confound results.

Data Collection: Baseline demographic and clinical information — including age, sex, body mass index (BMI), type and duration of diabetes, and comorbidities — were recorded for all participants. Fasting blood samples were collected for serum magnesium, fasting blood sugar (FBS), two-hour post-prandial blood sugar (PPBS), glycated haemoglobin (HbA1c), serum creatinine, blood urea nitrogen, and serum electrolytes. Each patient was clinically assessed for microvascular complications (nephropathy, neuropathy, retinopathy) and macrovascular complications (ischemic heart disease, cerebrovascular accident, peripheral vascular disease, transient ischemic attack). Details of concurrent medications — particularly diuretics and proton pump inhibitors — were documented.

Statistical Analysis: Data were analyzed using SPSS software. Continuous variables were expressed as means ± standard deviation (SD) and compared between groups using independent samples t-tests or non-parametric equivalents where appropriate. Categorical variables were assessed using chi-square or Fisher's exact tests. The prevalence of hypomagnesemia was compared against the expected population rate of 5% using a binomial test. A p-value < 0.05 was considered statistically significant.

Results

Demographic and Clinical Characteristics

The study enrolled 128 diabetic patients. Ages ranged from 22 to 70 years, with a mean age of 53.6 years (median 54 years). The two most represented age groups were 40–49 years (n = 36) and 60–69 years (n = 40). Males comprised 54.7% (n = 70) and females 45.3% (n = 58) of the cohort. BMI ranged from 18.6 to 27.2 kg/m², with the majority (48%) falling in the 24.1–26.0 kg/m² range, consistent with overweight status.

The type and duration distributions are shown in Tables 1 and 2.

Table 1. Age distribution of study participants (n = 128)

Age Group (years)

Frequency

20–29

3

30–39

0

40–49

36

50–59

28

60–69

40

70–79

1

Table 2. Diabetes type and duration among study participants

Variable

Category

Frequency (%)

Diabetes Type

Type 2

120 (93.8%)

 

Type 1

8 (6.2%)

Duration (years)

1–3

7 (5.5%)

 

3–5

10 (7.8%)

 

5–7

24 (18.8%)

 

7–9

22 (17.2%)

 

9–11

25 (19.5%)

 

11–13

21 (16.4%)

 

13–15

15 (11.7%)

Serum Magnesium Levels

Using the standard adult reference range for serum magnesium (1.7–2.4 mg/dL), 82 patients (64.1%) met criteria for hypomagnesemia, 31 (24.2%) had normal levels, and 15 (11.7%) had hypermagnesemia. The most densely populated interval was 1.6–1.7 mg/dL (60 patients), indicating that the majority of the cohort was not merely borderline low but clearly below the lower reference limit. The observed prevalence of hypomagnesemia (64.1%) was dramatically higher than the expected population rate of approximately 5%, a difference that was highly statistically significant (binomial p < 0.003). The distribution of serum magnesium values is presented in Table 3.

Table 3. Distribution of serum magnesium levels in diabetic patients (n = 128)

Serum Magnesium (mg/dL)

Frequency

Status

1.0–1.2

6

Hypomagnesemia

1.2–1.4

10

Hypomagnesemia

1.4–1.6

6

Hypomagnesemia

1.6–1.7

60

Hypomagnesemia

1.7–1.8

13

Normal

1.8–2.0

16

Normal

2.2–2.4

1

Normal

2.4–2.6

1

Hypermagnesemia

2.6–2.8

10

Hypermagnesemia

2.8–3.0

2

Hypermagnesemia

Glycaemic Control

Most participants demonstrated suboptimal glycaemic control. HbA1c was predominantly in the range of 8.6–11.2%, with only 3 patients (2.3%) achieving near-target values below 7.3%. FBS clustered in the 146–166 mg/dL range (47 patients), and PPBS was most common in the 191–211 mg/dL range. Higher HbA1c values were associated with lower serum magnesium levels, suggesting an inverse relationship between glycaemic control and magnesium status.

Diabetic Complications

The prevalence of microvascular and macrovascular complications is presented in Tables 4 and 5. Among microvascular complications, diabetic nephropathy was most prevalent (35.9%), followed by neuropathy (30.5%) and retinopathy (27.3%). Five patients (3.9%) presented with all three microvascular complications simultaneously. For macrovascular disease, ischemic heart disease (IHD) was the dominant complication (36.7%), while cerebrovascular accident (CVA) and peripheral vascular disease (PVD) were less common. Over half the cohort (57.8%) had no macrovascular complications.

Table 4. Microvascular complications in the study cohort (n = 128)

Complication

n (%)

Diabetic Nephropathy (any)

46 (35.9%)

Diabetic Neuropathy (any)

39 (30.5%)

Diabetic Retinopathy (any)

35 (27.3%)

No microvascular complication

42 (32.8%)

Nephropathy only

22 (17.2%)

Neuropathy only

17 (13.3%)

Nephropathy + Neuropathy

12 (9.4%)

Nephropathy + Retinopathy

7 (5.5%)

Neuropathy + Retinopathy

5 (3.9%)

All three complications

5 (3.9%)

Table 5. Macrovascular complications in the study cohort (n = 128)

Complication

Frequency

Percentage (%)

Transient Ischemic Attack (TIA)

0

0.0

Cerebrovascular Accident (CVA)

3

2.3

Ischemic Heart Disease (IHD)

47

36.7

Peripheral Vascular Disease (PVD)

4

3.1

No cardiovascular complication

74

57.8

Comorbidities and Medications

Hypertension was present in 74 patients (57.8%) — either alone (n = 61) or co-existing with CKD (n = 13). CKD was present in 38 patients (29.7%). Regarding medications, 60 patients (46.9%) were taking proton pump inhibitors (PPIs) and 30 (23.4%) were on diuretics. No patient was receiving chemotherapy. Patients on diuretics or PPIs had notably lower serum magnesium levels compared with those not on these agents, consistent with the known magnesium-depleting effects of both drug classes.

Association of Serum Magnesium with Complications

Patients with diabetic nephropathy had significantly lower mean serum magnesium than those without (p < 0.05). A similar trend toward lower magnesium was observed in patients with neuropathy and retinopathy, though these differences did not reach statistical significance, likely reflecting the modest sample size. Patients with CKD also demonstrated significantly lower mean serum magnesium (p < 0.05). No statistically significant difference in magnesium levels was found by sex, BMI category, or diabetes type. The mean serum magnesium was 1.58 mg/dL in Type 1 diabetics (n = 8) versus 1.76 mg/dL in Type 2 diabetics (n = 120), a difference that was not statistically significant (p = 0.107).

Discussion

This cross-sectional study provides important insights into the burden of hypomagnesemia in a tertiary care diabetic population in urban India. The principal finding — a 64.1% prevalence of serum magnesium below 1.7 mg/dL — is markedly higher than the background population rate of approximately 5%, and the difference is statistically overwhelming (p < 0.003). This confirms that diabetes mellitus is strongly associated with hypomagnesemia in the studied population, extending earlier reports from Indian and international cohorts [6,8,11].

The pathophysiological basis of this association is well established. Chronic hyperglycemia drives osmotic diuresis, which promotes renal magnesium wasting. Impaired insulin signaling in type 2 diabetes further disrupts intracellular magnesium transport, while dietary insufficiency and gastrointestinal malabsorption contribute additional risk in real-world patients [3,6,7]. The present findings, with the modal serum magnesium interval falling at 1.6–1.7 mg/dL, suggest that the majority of patients are not simply at the borderline but well within a clinically deficient range.

The most robust clinical association identified was between hypomagnesemia and diabetic nephropathy/CKD. Patients with either condition had significantly lower mean serum magnesium (p < 0.05). This is physiologically plausible: early diabetic nephropathy is characterized by tubular dysfunction that promotes urinary magnesium loss, before advanced CKD eventually leads to magnesium retention [12]. Magnesium deficiency may itself perpetuate glomerular injury through endothelial dysfunction, inflammation, and increased oxidative stress, acting both as a marker and a mediator of renal damage. These observations are consistent with findings by Pham et al. and Dasgupta et al., who reported inverse correlations between serum magnesium and renal function decline in diabetic cohorts [6,8].

For diabetic neuropathy and retinopathy, the trend toward lower serum magnesium in affected patients was consistent with the literature but did not reach statistical significance in this study. This is likely a function of sample size rather than the absence of a true association; magnesium's established roles in reducing oxidative stress, maintaining nerve conduction velocity, and supporting endothelial integrity provide a credible mechanistic basis for its involvement in both neuropathic and retinal complications [9,13]. Larger cohort studies, such as those utilizing NHANES data, have demonstrated inverse associations between magnesium intake and microvascular complication risk, though results have not always been significant after covariate adjustment.

The inverse relationship between serum magnesium and HbA1c observed in this cohort is consistent with the known bidirectional interaction between glycaemic control and magnesium status. Poor glycaemic control augments osmotic magnesium loss, while hypomagnesemia impairs insulin receptor tyrosine kinase activity and GLUT4 expression, worsening insulin resistance and glycaemic dysregulation [4,5]. This feedback loop underscores the clinical importance of addressing magnesium deficiency as part of comprehensive diabetes management.

The medication-related findings merit attention. Nearly half the cohort (46.9%) was on PPIs and approximately a quarter (23.4%) on diuretics — both well-recognized causes of secondary hypomagnesemia. PPIs reduce intestinal magnesium absorption through an as-yet incompletely understood mechanism, while loop and thiazide diuretics increase renal magnesium excretion [14]. In a population already predisposed to hypomagnesemia, co-prescription of these agents may substantially amplify deficiency risk. This finding supports the case for heightened vigilance and consideration of routine magnesium monitoring in diabetic patients receiving these drugs.

The dominant macrovascular complication in this cohort was IHD (36.7%), far exceeding the rates of CVA and PVD. This aligns with the well-documented excess coronary risk in diabetes and is consistent with the known cardioprotective roles of magnesium, which include blood pressure regulation, lipid modulation, prevention of vascular calcification, and reduction of arrhythmia risk [9,15]. While this study was not powered to demonstrate an independent association between magnesium status and macrovascular outcomes, the findings underscore the clinical importance of cardiovascular vigilance in this population.

This study has several limitations that should be acknowledged. The cross-sectional design precludes causal inference; longitudinal studies are required to determine whether correcting hypomagnesemia reduces complication rates. The absence of a non-diabetic control group limits direct comparison. Total serum magnesium was measured, which may not fully reflect biologically active ionized or erythrocyte magnesium stores. Some data were missing or incomplete, and residual confounding from dietary, socioeconomic, or lifestyle factors cannot be entirely excluded. The small number of Type 1 diabetic patients (n = 8) limits subgroup analysis by diabetes type.

Conclusions

Hypomagnesemia is a highly prevalent yet underrecognized metabolic derangement in patients with diabetes mellitus, affecting nearly two-thirds of this study cohort — a rate more than twelve times the expected population prevalence. The association of low serum magnesium with diabetic nephropathy and chronic kidney disease was statistically significant, and consistent trends were observed for neuropathy and retinopathy. An inverse relationship between serum magnesium and HbA1c further highlights the interplay between magnesium status and glycaemic control. Medication-related magnesium depletion, particularly from diuretics and PPIs, represents a modifiable and often overlooked contributor to hypomagnesemia in this population.

These findings collectively support the routine incorporation of serum magnesium assessment into diabetic clinical practice, particularly in patients with evidence of nephropathy, CKD, or those receiving magnesium-depleting medications. Prospective interventional studies evaluating the impact of magnesium repletion on glycaemic control and complication rates in well-characterized diabetic cohorts are warranted.

Acknowledgements

The authors acknowledge the support of the Department of General Medicine, the institutional ethics committee for their approval, and all study participants for their voluntary contribution. No external funding was received for this study.

References

[1]    Barbagallo M, Dominguez LJ. Magnesium and type 2 diabetes. World J Diabetes. 2015; 6(10):1152–1157.

[2]    Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2007; 2(2):366–373.

[3]    de Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium basics. Clin Kidney J. 2015; 8(3):317–327.

[4]    Barbagallo M, Dominguez LJ. Effects of magnesium deficiency on mechanisms of insulin resistance. Nutrients. 2020; 12(6):1351.

[5]    Gommers LM, Hoenderop JGJ, Bindels RJM, de Baaij JHF. Hypomagnesemia and cardiovascular risk in type 2 diabetes. Endocr Rev. 2023; 44(3):357–376.

[6]    Pham PC, Pham PM, Pham PA, Pham SV, Pham HV, Miller JM, et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol. 2005; 63:429–436.

[7]    Rodríguez-Morán M, Guerrero-Romero F. Hypomagnesemia in type 2 diabetes: a vicious circle? Diabetes. 2023; 65(1):3–5.

[8]    Dasgupta A, Sarma D, Saikia UK. Hypomagnesemia in type 2 diabetes mellitus. Indian J Endocrinol Metab. 2012; 16(6):1000–1003.

[9]    Sharma A, Dabla S, Agrawal RP, Barjatya H, Kochar DK, Kothari RP. Serum magnesium: an early predictor of course and complications of diabetes mellitus. J Indian Med Assoc. 2007; 105(1):16–20.

[10]     Kumar P, Bhargava S, Agarwal PK, Garg A, Khosla A. Association of serum magnesium with type 2 diabetes mellitus and diabetic retinopathy. J Family Med Prim Care. 2019; 8(5):1671–1677.

[11]    Batar PK. Study of serum magnesium level in diabetes mellitus and its correlation with micro and macro complications. J Assoc Physicians India. 2022; 70(4):11–12.

[12]    Kao WH, Folsom AR, Nieto FJ, Mo JP, Watson RL. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: The atherosclerosis risk in communities study. Arch Intern Med. 1999; 159(21):2151–2159.

[13]    Song Y, He K, Levitan EB, Manson JE, Liu S. Effect of magnesium supplementation on glucose metabolism in people with diabetes: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2016; 70(11):1354–1360.

[14]    Veronese N, Watutantrige-Fernando S, Luchini C, Solmi M, Sartore G, Sergi G, et al. Oral magnesium supplementation for treating glucose metabolism disorders: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2021; 13(22):4074.

[15]    Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care. 2003; 26(4):1147–1152.
 


IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications